MANHASSET, New York, July 30 /PRNewswire/ --

- Research, Best Practices and Expert Commentary to Help Businesses Succeed Amid Rapid Change

TechWeb, a division of United Business Media LLC, in conjunction with Satyam, Computer Services, Ltd. (NYSE: SAY), a leading global consulting and information technology services provider, launched TransformationEnablers.com, a new source of research, insights and expert commentary on how businesses can apply technology to transform their processes, practices and technologies for strategic advantage.

LONDON, July 30 /PRNewswire/ --

- Justoffbase Marks Fourth Successful Year Running Entire Estore with NetSuite Ecommerce

NEW YORK, July 30 /PRNewswire/ --

- With Photo

- Benefit T-Shirt Design By Karl Lagerfeld

- A Women's Cancer Initiative in Partnership with the Entertainment Industry Foundation's Women's Cancer Research Fund

Saks Fifth Avenue and the Entertainment Industry Foundation (EIF) announced today that Academy Award(R) winning actress Gwyneth Paltrow has been named the Entertainment Industry Foundation ambassador for Saks Fifth Avenue's 2008 KEY TO THE CURE campaign. KEY TO THE CURE is a women's cancer initiative founded in partnership with EIF's Women's Cancer Research Fund. The program will also receive ongoing support from Mercedes-Benz USA.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080730/NYW052)

MUMBAI, July 30 /PRNewswire/ -- Sun Pharmaceutical Industries Ltd. announced that USFDA has granted final approval for the Company's Abbreviated New Drug Application (ANDA) for generic Depakote (R), divalproex sodium delayed release tablets.

Divalproex sodium delayed release tablets are indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures, as sole and adjunct therapy for patients with simple and complex absence seizures, for the treatment of the manic episodes associated with bipolar disorders, as well as for prophylaxis of migraine headaches.

MARKHAM, Canada and OSAKA, Japan, July 30 /PRNewswire/ -- Cytochroma and Mitsubishi Tanabe Pharma Corporation ("MTPC") today announced that the companies have signed a license agreement under which Cytochroma granted MTPC an exclusive license in the U.S. and Asia, including Japan, to develop and commercialize CTA018, Cytochroma's novel vitamin D analog. CTA018 is entering Phase II development in Canada for the treatment of secondary hyperparathyroidism ("SHPT") in patients with chronic kidney disease ("CKD"). The agreement also grants MTPC access to certain follow-on compounds to CTA018 for the same territories, with Cytochroma retaining all rights to CTA018 and these follow-on compounds in all regions outside the U.S. and Asia.

LONDON, July 30 /PRNewswire/ --

- With Photo

Whilst the media is currently full of doom mongering about the credit crunch, many Brits are turning these challenging times to their advantage by planning a career change, taking steps to create a better work:life balance or finally fulfilling that dream of setting up a successful online business.